Research programme: anticancer therapeutic antibodies - Merck Serono/MorphoSys
Latest Information Update: 16 Jun 2014
At a glance
- Originator Merck Serono; MorphoSys
- Class Monoclonal antibodies
- Mechanism of Action Checkpoint kinase inhibitors; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 12 Jun 2014 Early research in Cancer in Germany (unspecified route)